Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

Polaryx Therapeutics, Inc., clinical-stage biotechnology company, develops small molecule and gene therapy treatments for lysosomal storage disorders. Its pipeline includes PLX-100, a preclinical ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

Just over a decade after being acquired by Daiichi Sankyo, US biotech Plexxikon will be shuttered at the end of March, with its R&D projects transferred to other areas of the Japanese group. It's the ...

Explore the NYSE:PLX financials. Find the Protalix financial statements for a comprehensive overview of the company’s financial health. This summary highlights critical numbers from key financial ...

Atlanta, GA-based industrial technology manufacturer Acuity Brands agreed to acquire QSC, LLC for $1.1 billion. Terms of the transaction were not disclosed. The net purchase price represents ...